Last updated: July 3, 2023
Sponsor: Sun Jie
Overall Status: Active - Recruiting
Phase
N/A
Condition
Primary Biliary Cholangitis
Treatment
Proteomic sequencing
Clinical Study ID
NCT05932927
2022-096
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- chronic hepatitis Agreed to venous blood collection
Exclusion
Exclusion Criteria:
- pneumonia, pulmonary vascular disease, interstitial pulmonary disease, COPD, bronchialasthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinalbleeding.
Study Design
Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Proteomic sequencing
Phase:
Study Start date:
April 01, 2023
Estimated Completion Date:
June 01, 2024
Study Description
Connect with a study center
No.8, Xitoutiao, Youan Men Wai, Fengtai District
Beijing, 100038
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.